No Data
No Data
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM): Is Breakeven Near?
Buy Rating Affirmed for Rhythm Pharmaceuticals: Promising Phase 3 Results for Setmelanotide in Obesity Treatment
Rhythm Pharmaceuticals Insider Sold Shares Worth $1,248,490, According to a Recent SEC Filing